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A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent vinflunine in patients with advanced non-
small-cell lung cancer (NSCLC) previously treated with a platinum-based regimen. The objectives were to assess efficacy in terms of
tumour response rate (primary end point), duration of response, progression-free survival (PFS) and overall survival (OS), and to
evaluate the toxicity associated with this treatment. Patients with advanced NSCLC with progressive disease having failed prior
platinum-based first-line treatment for advanced disease. Five responses out of the 63 treated patients were documented by WHO
criteria and validated by an independent panel review (IRP), yielding a response rate of 7.9% (95% CI: 2.6–17.6) in the intent-to-treat
analysis and 8.3% (95% CI: 2.8–18.4) in the evaluable population. Disease control was achieved in 35 out of 60 evaluable patients
(58.3%). The median duration of response (complete responseþpartial response), according to modified WHO criteria was 7.8
months (95% CI: 4.6–NR). Median PFS was 2.6 months (95% CI: 1.4–3.8), and the median survival was 7.0 months (95% CI: 5.8–
9.2). Grades 3–4 neutropenia was reported in 50% of patients; febrile neutropenia was observed in two patients (3.2%); grades 3–4
myalgia and grade 3 constipation were experienced by 10 (15.9%) and six (9.5%) of patients, respectively. Constipation was
manageable, noncumulative and could be prevented with laxative prophylaxis. The encouraging results from this phase II study with
vinflunine warrant further investigations in phase III trials as second- or first-line treatment of advanced non-small-cell lung carcinoma,
as a single agent or in combination with other active drugs.
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Patients with newly diagnosed inoperable stage (IIIB–IV) lung
cancer and reasonable performance status should receive treat-
ment with at least one chemotherapy regimen and it is now
accepted that the schedule should be platinum based, in
combination with a newer agent such as a taxane, vinorelbine or
gemcitabine (Kelly et al, 2001; Schiller et al, 2002). The benefits of
this approach are relatively modest; however, patients who
progress on or after first-line chemotherapy for advanced disease
but continue to be in good general condition may be offered
second-line chemotherapy. Currently, three drugs are approved for
second-line therapy of non-small-cell lung cancer (NSCLC)
(docetaxel, erlotinib and pemetrexed), however, the life expectancy
of these patients remains short and new drugs are urgently needed
for this setting.
Vinflunine (Javlor
s, Pierre Fabre Me ´dicament, Boulogne-Bill-
ancourt, France) is a novel tubulin-targeted agent obtained by
semisynthesis using superacidic chemistry to selectively introduce
two fluorine atoms at the 200 position of catharanthine moiety of
vinca alkaloid (Fahy et al, 1997). The actions of vinflunine on
microtubules produce effects on mitotic spindle functions leading
to modifications of cell cycle progression and cell killing (Ngan
et al, 2000) Vinflunine prevents microtubule assembly during
mitosis (Etie ´vant et al, 1998; Kruczynski et al, 1998; Ngan et al,
2001). The affinity profile of vinflunine shows features which
suggest that it will have greater effects on mitotic rather than
axonal tubulin and so will not cause significant neurotoxicity
(Lobert et al, 1998). Vinflunine showed antitumour activity in
xenografts tested and high in vivo activity against the NCI H69
human NSCLC model (Hill et al, 1999; Kruczynski et al, 1999).
Vinflunine treatment every 3 weeks was considered optimal, based
on clinical and pharmacokinetic data from the three dose
schedules evaluated in Phase I trials. Vinflunine was administered
at the beginning of the phase I trials at 350mgm
 2 in normal
saline as a 10-min infusion; after an early safety analysis this dose
was adjusted at 320mgm
 2 which is the recommended dose for all
subsequent patients included in clinical trials (Bennouna et al,
2003). The preclinical profile of vinflunine suggests that this first
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sfluorinated antitubulin compound is a good candidate for second-
line chemotherapy in patients with advanced NSCLC cancer after
failure of standard platinum-based chemotherapy.
MATERIALS AND METHODS
Objectives
This study was an open-label, multicentre, nonrandomised phase
II trial designed to determine the efficacy of vinflunine in patients
with advanced NSCLC with clear evidence of metastatic disease
who had failed platinum-based therapies for advanced disease. The
primary objective was to measure response rate by WHO criteria;
secondary objectives were to assess duration of response,
progression-free survival (PFS) and overall survival (OS) and to
evaluate the toxicity associated with this treatment. The protocol
and its amendments were submitted to Independent Ethics
Committees (IEC) according to local requirements. The study
was conducted in accordance with the ethical principles set forth
in the Declaration of Helsinki (Somerset West 1996) and in
compliance with Good Clinical and Laboratory Practices. Written
informed consent was obtained from each participating patient
prior to entry into the study.
Patient selection
Patients were recruited from seven active centres between October
2001 and May 2003. Patients eligible for the study were required to
have a histologically confirmed diagnosis of NSCLC cancer with
clear radiological or clinical evidence of progressive disease (PD).
Previous systemic chemotherapy or radiotherapy had to have been
stopped 30 days before the administration of the study drug, and
a full recovery from all side effects was necessary. The presence of
at least one bidimensionally measurable lesion, not previously
irradiated, assessed by CT-scan or MRI performed o28 days
before 1st day of study drug administration was required. Patients
were required to be aged X18 years with Karnofsky Performance
Status (KPS)X80 and an estimated life expectancy of X12 weeks.
Evidence of adequate haematological function (absolute neutrophil
count (ANC) X2.0 10
9l
 1, platelets X100 10
9l
 1), hepatic
function (bilirubin p1.5 upper normal limit (UNL), transami-
nases p2.5 UNL, unless due to liver involvement), normal renal
function and a normal ECG was required.
Treatment schedule
Vinflunine was given at the dose of 320mgm
 2 as a 10-min
infusion every 21 days. Tolerance was assessed throughout the
treatment period and before each administration according to the
NCI Common Toxicity Criteria (Version 2.0). All patients who
received at least one vinflunine administration were considered
as evaluable for safety. The use of haematopoietic growth factors
(G-CSF) was allowed for patients with febrile neutropenia or
neutropenic infections according to local guidelines. Vinflunine
had to be delayed by 1 or 2 weeks in the case of haematological or
nonhaematological toxicity (grade 42 toxicity impacting a major
organ except for alopecia). If febrile neutropenia and/or a grade 4
neutropenia (o 1.0 10
9l
 1) lasting 7 days or more was observed
between 2 subsequent administrations of vinflunine, the dose was
reduced to 280mgm
 2 from the next cycle on. If, after a dose
reduction, this toxicity was seen again with the same severity, the
dose was further reduced to 250mgm
 2. If at this dose level the
same event recurred, the treatment was stopped. Blood counts
were to be performed every 2 days until recovery of ANC
X1.0 10
9l
 1. No dose re-escalation was allowed after dose
reduction. In case of grade 2 mucositis and/or constipation lasting
more than 5 days, or grade X3 mucositis, and/or constipation of
any duration, the vinflunine dose was reduced to 280mgm
 2 from
the next cycle on. If, after dose reduction, one of these toxicities
was seen again, the dose was reduced to 250mgm
 2. If at this dose
the event recurred, the treatment was discontinued. Each patient
had to receive at least two cycles of treatment unless early
progression, unacceptable toxicity, serious intercurrent illness,
other reactions occurred which could affect the clinical status of
the patient to a significant degree requiring discontinuation of the
drug, or request by the patient to withdraw consent.
After the initial two cycles, tumour response was assessed; for
patients showing PD the treatment had to be discontinued;
patients showing stable disease (SD) received two further cycles
of vinflunine, after a second assessment treatment could be
continued at the Investigator’s discretion; patients presenting with
a complete or a partial response (CR, PR) could continue
treatment until PD, toxicity or patient preference precluded
further therapy.
Baseline and treatment evaluation
Preregistration assessments included a detailed medical history,
CT-scan, MRI or physical examination (in case of superficial
lymph node or skin nodule) for tumour assessment. All positive
imaging procedures at study entry had to be repeated every 6
weeks. An assessment of symptoms was made at study entry and
then throughout treatment. Physical examination and vital signs
were assessed on day one of each cycle. A complete blood cell
count (including a differential and platelet count) was taken at
baseline (within a maximum of 7 days prior to study drug
administration) and during treatment, before each cycle. Addi-
tional samplings were planned on day 8s and 15 of each cycle: in
case the ANC was o 1.0 10
9l
 1, counts were repeated every 2
days until recovery to ANC X1.0 10
9l
 1. Transaminases, alka-
line phosphatases, total bilirubin, lactate dehydrogenase, creati-
nine, electrolytes including Ca
2þ,N a
þ and K
þ and total protein
were assessed at every cycle. Electrocardiogram was to be
performed and recorded prior to initial administration and
repeated at every cycle.
If PD had not occurred during the study treatment period, all
lesions were regularly assessed until disease progression. Efficacy
was assessed by investigators and subsequently by an Independent
Review Panel (IRP) using both the WHO criteria (World Health
Organisation, 1979; Green and Weiss, 1992) and RECIST guidelines
(Therasse et al, 2000); CR was defined as disappearance of all
lesions clinically and radiologically. Partial response was defined
as X50% reduction in the sum of the products of perpendicular
diameters of all lesion measurements maintained for at least 4
weeks while no other type of lesion progressed or appeared. Stable
disease was defined as o50% reduction and o25% increase in the
sum of the products of perpendicular diameters of all lesion
measurements maintained for at least 4 weeks while no other type
of lesion progressed or appeared. All responses and disease
stabilisations (if appropriate) were reviewed by an independent
radiologist. The duration of response was calculated for patients
with confirmed response (CR or PR) from the date of registration
until the date of documented progression, start of new anticancer
therapy, date of death, lost follow-up or last news. The PFS was
defined as the time elapsed from registration until progression,
death, lost follow-up or last news; survival was defined as the time
elapsed from registration date to death or lost to follow-up, or last
date the patient was known to be alive.
Statistical analysis
Sample size was based on a one-sample multiple testing procedure
(Fleming, 1982). With 55 evaluable patients, a null hypothesis for
the true response rate of 4% and an alternative hypothesis of 14%,
the type I error a was 5% and the type II error b was less than 20%.
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sContinuous data were summarised using median, minimum and
maximum values. Categorical data were presented in contingency
tables with frequencies and percentages. Exact confidence intervals
were calculated at the 95% level. Time dependent parameters were
analysed using the Kaplan–Meier method and 95% confidence
interval for the median was reported.
Efficacy analyses were performed on the intent to treat and
evaluable population. The primary efficacy parameter was
response rate and included only confirmed CR and PR. The other
efficacy parameters were duration of response, PFS and OS.
Safety analyses were performed on the population of patients
having received at least one dose of study treatment. Worst NCI
CTC grade for haematological and nonhaematological adverse
events were presented.
All statistical analyses were carried out with 8.2 version of SAS
s
(SAS Institute Inc., Cary, NC, USA) for Windows
s.
RESULTS
Sixty-six patients with advanced or metastatic NSCLC were
included in this study. Three patients who were included but not
treated as they presented with intercurrent serious conditions after
signing informed consent, were not included in the analysis. In line
with the ICH E9 guidelines in which it states that only treated
patients should be reported, the intent-to-treat analysis therefore
includes 63 patients; an additional three patients were found to be
ineligible after enrolment, hence results will also be presented for
the 60 evaluable patients.
Evaluation of efficacy
Demographic features of the patients are summarised in Table 1.
As planned, all patients had previously received chemotherapy
including platinum (cisplatin or carboplatin or both). All but two
patients had received this chemotherapy for advanced disease. The
median treatment-free interval after platinum-based chemother-
apy was 4.4 months (range 0.5–30.2 months). All patients enrolled
in the study had clear evidence of PD, 74.6% had two or more
metastatic lesions at entry. According to WHO criteria, five
responses out of the 63 treated patients were documented and
validated by an IRP, yielding a response rate of 7.9% (95% CI: 2.6–
17.6) in the intent-to-treat analysis and 8.3% (95% CI: 2.8–18.4) in
the evaluable population. The previous treatment of these patients
consisted of carboplatin plus paclitaxel for four patients and
cisplatin plus gemcitabine for one patient. The response rate was
also analysed by the IRP using RECIST criteria: six patients were
assessed as responders, yielding a response rate of 9.5% (95% CI:
3.6–19.6) in the intent-to-treat analysis and 10% (95% CI: 3.8–
20.5) on the evaluable population as shown in Table 2. Disease
control, that is the absence of PD (CRþPRþSD by WHO criteria)
was achieved in 35 patients out of the 60 evaluable (58.3%)
patients.
The median duration of response (CRþPR), according to WHO
criteria was 7.8 months (95% CI: 4.6–NR). Median PFS was 2.6
months (95% CI: 1.4–3.8). The median survival time was 7 months
(95% CI: 5.8–9.2) (Figures 1 and 2). Twenty-two patients (34.9%)
received at least one further chemotherapy after study disconti-
nuation (16 patients received monotherapy as follows: docetaxel:
12 patients; gemcitabine: two patients; irinotecan: one patient; and
experimental agent: one patient; six patients underwent further
chemotherapy with a combination regimen; cisplatin–vinorelbine:
two patients; gemcitabine–docetaxel, gemcitabine–carboplatin,
mitomycin C–vinblastine–cisplatin and docetaxel–carboplatin:
one patient, respectively).
Table 1 Demographic data
Age (years)
Median 61.6
Range (38.7–78.7)
Patients (n¼63) %
Sex
Male 47 74.6
Female 16 25.4
Karnofsky PS Status
100 14 22.2
90 21 33.3
80 28 44.4
Histopathologic type
Adenocarcinoma 35 55.6
Squamous cell carcinoma 18 28.6
Large cell carcinoma 3 4.8
Not specified 7 11.1
Treatment type
Chemotherapy alone 38 60.3
Radiotherapy+chemotherapy 11 17.5
Surgery+chemotherapy 10 15.8
Surgery+radiotherapy+chemotherapy 4 6.4
Chemotherapy
Carboplatin–paclitaxel 15 23.8
Carboplatin–gemcitabine 13 20.6
Carboplatin–docetaxel 4 6.3
Carboplatin–vinorelbine 1 1.6
Cisplatin–vinorelbine 12 19
Cisplatin–gemcitabine 8 12.7
Cisplatin–mitomycin C–vinblastine 6 9.5
Cisplatin–mitomycin C–ifosfamide 2 3.2
Carboplatin–docetaxel–gemcitabine 1 1.6
Cisplatin–vinorelbine–ifosfamide 1 1.6
Table 2 Overall response rate
ITT population Evaluable population
WHO RECIST WHO RECIST
Number of patients 63 63 60 60
Complete response (CR) — — — —
Partial response (PR) 5 (7.9%) 6 (9.5%) 5 (8.3%) 6 (10%)
Overall response (CR+PR) 5 (7.9%) 6 (9.5%) 5 (8.3%) 6 (10%)
95% Confidence interval (2.6–17.6) (3.6–19.6) (2.8–18.4) (3.8–20.5)
Stable disease 31 (49.2%) 31 (49.2%) 30 (50%) 30 (50%)
Disease control (CR+PR+NC) 36 (57.1%) 37 (58.7%) 35 (58.3%) 35 (58.3%)
Disease progression (PD) 25 (39.7%) 24 (38.1%) 25 (41.7%) 24 (40%)
Not evaluable 2 (3.2%) 2 (3.2%)
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at baseline and before each treatment cycle during the study
(i.e. every 3 weeks). Ten out of 63 patients (15.9%) had an
improvement of their KPS during treatment and 36 (57.1%)
maintained their baseline KPS. Only 15 patients (23.8%) had a
worsening KPS during treatment.
Evaluation of safety
The total number of cycles delivered was 223 (median number was
2 (range 1–9)). The median relative dose intensity by patient was
99.4% of the theoretical scheduled dose. Seventeen out of 63
patients (27%) (32.5% of cycles) had dose reductions. Fourteen
patients (22.2%) had at least one cycle delayed; 20 cycles were
postponed as follows: five delays X4 days and o7 days, 11 delays
between 7 and 14 days and four delays X14 days. Six delays were
due either to drug related haematological toxicity (four) or to
drug-related nonhaematological toxicity (two); the other 14 cycles
were postponed due to adverse events unrelated to the study drug
and logistical or administrative issues.
Grade 3/4 neutropenia was observed in 50% of patients but only
two patients experienced febrile neutropenia (3.2%), and 3.2%
neutropenic infection. No prophylactic growth factors were
allowed. Although growth factors were permitted for the treatment
of febrile neutropenia or grade 4 neutropenia without infection no
patient in the study received this intervention. grade 3 anaemia
was observed in 6.5% of patients but no grade 4 anaemia was
reported; thrombocytopenia was rare (Table 3). Grade 3/4 myalgia
was observed in 15.9% of patients; six out 63 patients suffered
from grade 3 constipation (9.5%) that was reported in five patients
after the first dose; no grade 4 constipation was reported. Severe
fatigue, arthralgia anorexia, abdominal pain and stomatitis were
uncommon and observed in o6% of patients (Table 4).
No clinical significant alterations in biological parameters were
observed. (creatinine, total bilirubin, SGOT/AST, SGPT/ALT and
alkaline phosphatase).
DISCUSSION
Although in 1997, ASCO guidelines stated that there was no
current evidence that second-line chemotherapy improved survival
with advanced NSCLC (American Society of Clinical Onology,
1997) there are now a number of trials which have demonstrated
benefit for patients with disease progression after first-line
chemotherapy (Biesma et al, 1999) including a number of studies
which have documented a quality of life benefit (Dancey et al,
1999; Miller et al, 1999).
Results of the phase II study presented here have demonstrated
that vinflunine has clinically relevant activity as second-line
treatment of patients with NSCLC who have failed first-line
treatment with a platinum-containing regimen. The overall
response rate of 8% and a median OS of over 7 months compares
favourably with reports in the literature on the use of best
supportive care and of other new agents. At the current time only
erlotinib, docetaxel and pemetrexed are approved for the
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Figure 1 Progression-free survival.
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Figure 2 Overall survival.
Table 3 Haematological (NTC CTC, Version 2.0) drug-related adverse events
N¼62
a patients N¼221
a cycle
Overall incidence Grade 3 Grade 4 Overall incidence Grade 3 Grade 4
Haematological n % n % n % n % n % n %
Anaemia 55 88.7 4 6.5 0 0 177 80.1 4 1.8 0 0
Leucopenia 53 85.5 15 24.2 5 8.1 147 66.5 25 11.3 7 3.2
Neutropenia 51 82.3 16 25.8 15 24.2 150 67.9 35 15.8 23 10.4
Thrombocytopenia 21 33.9 3 4.8 0 0 57 25.8 3 1.4 0 0
Febrile neutropenia 2 3.2 2 3.2 0 0 2 0.9 2 0.9 0 0
Infection with G3/4 neutropenia 2 3.2 2 3.2 0 0 2 0.9 2 0.9 0 0
aOne patient was not evaluable for haematological toxicity.
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The application for broadening the indication of docetaxel
to include second-line chemotherapy of patients with locally
advanced or metastatic NSCLC was based on the results of a phase
III study of docetaxel vs vinorelbine/ifosfamide (Fossella et al,
2000) and another phase III study of docetaxel vs supportive
care. The first study (Shepherd et al, 2000) failed to show a
significant effect on the primary end point (OS), while it showed
a significant increase in one secondary end point, the response
rate, which was 10.5 and 6.5% for docetaxel 100 and 75mgm
 2,
respectively, compared with 0.8% in the vinorelbine/ifosfamide.
The study comparing docetaxel with supportive care in previously
treated patients was analysed in two parts corresponding to
two successive periods and doses of docetaxel: 100 and 75mgm
 2.
In this study a significant increase in OS (P¼0.016) was observed.
Docetaxel treatment also showed positive effects in several
secondary endpoints of this study including the overall response
rate of 6%; time to progression was significantly improved
in the overall docetaxel group (10.6 vs 6.7 weeks), as well
as in docetaxel 75mgm
 2 (12.3 vs 7 weeks) and in docetaxel
100mgm
 2 subgroups (9.1 vs 5.9 weeks). The lower dose
was generally better tolerated than in the higher dose. Recently,
pemetrexed has demonstrated an overall response rate of 9% and
8-month median survival in a phase III trial comparing this drug
with docetaxel; differences with the latter were generally limited to
toxicity, with pemetrexed-treated patients experiencing less
myelosuppression and fewer hospitalisations (Hanna et al,
2004). The double-blind placebo-controlled trial of erlotinib has
shown that this drug significantly increases the PFS by 2 weeks and
the OS by 2 months in comparison with best supportive care
and placebo; the median OS of 6.7 months in erlotinib-treated
patients in this trial is comparable with the results of the other
agents (Shepherd et al, 2005). The role of gemcitabine and
ixabepilone in the management of NSCLC patients who have
failed first-line therapy is not yet clear due to the lack of phase III
trial data in this setting (Rosvold et al, 1998; Vansteenkiste et al,
2003).
The toxicity profile of vinflunine is also acceptable by
comparison with the other candidate agents; the most frequent
adverse events observed were neutropenia in 50% of patients;
however, only 3.2% developed febrile neutropenia; grade 3
constipation was observed in 9.5% of patients, but was manage-
able, noncumulative and could be prevented with prophylactic
treatment.
The encouraging results from this phase II study with vinflunine
warrant further investigations in phase III trials as second or first
line treatment of advanced non-small cell lung carcinoma, as a
single agent or in combination with other active drugs. Currently, a
phase III trial comparing vinflunine with docetaxel in second-line
treatment of NSCLC is ongoing.
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